CRT 2026
Heart Failure
JoAnn Lindenfeld, MD
Director, Heart Failure and Transplantation
Vanderbilt University
Nashville, Tennessee, United States
Disclosure information not submitted.
Chaim Shaul Lotan, MD
Chief Innovation Officer
Hadassah-Hebrew University Medical Center
Jerusalem, Israel
Disclosure(s): No financial relationships to disclose
James Udelson, MD
Chief, Division of Cardiology
Tufts Medical Center
Boston, Massachusetts, United States
Disclosure(s): Alleviant: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); FIRE1: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Reprieve: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing)
Vijay Iyer, MD, PhD
Associate Professor
University at Buffalo
East Amherst, New York, United States
Disclosure information not submitted.
Navin K. Kapur, MD, FSCAI FAHA FACC
Professor of Medicine
Tufts Medical Center
Boston, Massachusetts, United States
Disclosure information not submitted.
Dean J. Kereiakes, MD, FACC, MSCAI
Chairman, The Christ Hospital Heart and Vascular Institute; Medical Director, The Christ Hospital Research Institute; Professor of Clinical Medicine, The Ohio State University
The Christ Hospital Health Network
Cincinnati, Ohio, United States
Disclosure information not submitted.
Scott M. Lilly, MD PhD
Professor
The Ohio State University Wexner Medical Center
Columbus, Ohio, United States
Disclosure(s): Cardiac Dimensions: Consulting Fees (e.g., advisory boards) (Ongoing); Edward Lifesciences: Consulting Fees (e.g., advisory boards) (Ongoing)
JoAnn Lindenfeld, MD
Director, Heart Failure and Transplantation
Vanderbilt University
Nashville, Tennessee, United States
Disclosure information not submitted.
Miguel Pinilla Vera, MD
Advanced Heart Failure Cardiologist
Medstar Washington Hospital Center
Washington, District of Columbia, United States
Disclosure(s): No financial relationships to disclose
Gregg W. Stone, MD, FACC, MSCAI
Physician
Mount Sinai
New York, New York, United States
Disclosure(s): Cardiac Success, Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Valfix, Xenter, Vascentis: Stock-privately held company (Ongoing); Cardiac Success, Occlutech, Ablative Solutions, Oxitope, Elixir, Impulse Dynamics, Asceneuron, Myochron, Vesalio: Consulting Fees (e.g., advisory boards) (Terminated); Colibri, Remote Cardiac Enablement, Valfix, Zoll, HeartFlow, Shockwave, Ancora, Adona Medical, Abbott, HighLife, Elucid Bio, Aria, Alleviant, FBR Medical, Bioventrix, MedHub, Biotyx Medical: Consulting Fees (e.g., advisory boards) (Ongoing); Shockwave, Biosense-Webster, Bioventrix, Abbott, Abiomed, Cardiovascular Systems Inc, Phillips, Pulnovo, V-wave and PCORI via Weill Cornell Medical Center.: Grant/Research Support (Ongoing)